IL303083A - 19-NOR C3,3-C21-N-pyrazolyl steroid dimer and methods of using it - Google Patents
19-NOR C3,3-C21-N-pyrazolyl steroid dimer and methods of using itInfo
- Publication number
- IL303083A IL303083A IL303083A IL30308323A IL303083A IL 303083 A IL303083 A IL 303083A IL 303083 A IL303083 A IL 303083A IL 30308323 A IL30308323 A IL 30308323A IL 303083 A IL303083 A IL 303083A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- sleep
- subject
- administered
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558703P | 2017-09-14 | 2017-09-14 | |
| US201862624680P | 2018-01-31 | 2018-01-31 | |
| US201862624678P | 2018-01-31 | 2018-01-31 | |
| US201862653189P | 2018-04-05 | 2018-04-05 | |
| PCT/US2018/051048 WO2019055764A1 (en) | 2017-09-14 | 2018-09-14 | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL303083A true IL303083A (en) | 2023-07-01 |
Family
ID=65723895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL303083A IL303083A (en) | 2017-09-14 | 2018-09-14 | 19-NOR C3,3-C21-N-pyrazolyl steroid dimer and methods of using it |
| IL273126A IL273126A (en) | 2017-09-14 | 2020-03-08 | 19-NOR C3,3-dimethyl C21-N-pyrazolyl steroid and methods of using it |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273126A IL273126A (en) | 2017-09-14 | 2020-03-08 | 19-NOR C3,3-dimethyl C21-N-pyrazolyl steroid and methods of using it |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220110949A1 (enExample) |
| EP (2) | EP3681510A1 (enExample) |
| JP (3) | JP2020534270A (enExample) |
| AU (2) | AU2018334214A1 (enExample) |
| CA (1) | CA3075872A1 (enExample) |
| IL (2) | IL303083A (enExample) |
| MX (3) | MX2020002889A (enExample) |
| TW (2) | TW202339764A (enExample) |
| WO (1) | WO2019055764A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ773177A (en) | 2012-01-23 | 2022-09-30 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| AU2014256229B2 (en) | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| NZ791594A (en) | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CA3163556A1 (en) * | 2019-12-05 | 2021-06-10 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014256229B2 (en) * | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| HUE051488T2 (hu) * | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| NZ791594A (en) * | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
-
2018
- 2018-09-14 EP EP18786464.0A patent/EP3681510A1/en not_active Withdrawn
- 2018-09-14 US US16/647,203 patent/US20220110949A1/en not_active Abandoned
- 2018-09-14 JP JP2020514950A patent/JP2020534270A/ja active Pending
- 2018-09-14 TW TW111150395A patent/TW202339764A/zh unknown
- 2018-09-14 CA CA3075872A patent/CA3075872A1/en active Pending
- 2018-09-14 TW TW107132510A patent/TW201919642A/zh unknown
- 2018-09-14 IL IL303083A patent/IL303083A/en unknown
- 2018-09-14 AU AU2018334214A patent/AU2018334214A1/en not_active Abandoned
- 2018-09-14 WO PCT/US2018/051048 patent/WO2019055764A1/en not_active Ceased
- 2018-09-14 EP EP23150618.9A patent/EP4218767A1/en active Pending
- 2018-09-14 MX MX2020002889A patent/MX2020002889A/es unknown
-
2020
- 2020-03-08 IL IL273126A patent/IL273126A/en unknown
- 2020-03-13 MX MX2023010064A patent/MX2023010064A/es unknown
- 2020-03-13 MX MX2023010063A patent/MX2023010063A/es unknown
-
2023
- 2023-01-24 JP JP2023008782A patent/JP2023038310A/ja active Pending
- 2023-03-01 US US18/176,571 patent/US20230201224A1/en not_active Abandoned
-
2024
- 2024-06-05 JP JP2024091642A patent/JP2024107137A/ja active Pending
- 2024-08-07 AU AU2024205601A patent/AU2024205601A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230201224A1 (en) | 2023-06-29 |
| EP4218767A1 (en) | 2023-08-02 |
| WO2019055764A1 (en) | 2019-03-21 |
| TW202339764A (zh) | 2023-10-16 |
| MX2023010064A (es) | 2023-09-06 |
| AU2024205601A1 (en) | 2024-08-29 |
| JP2024107137A (ja) | 2024-08-08 |
| TW201919642A (zh) | 2019-06-01 |
| AU2018334214A1 (en) | 2020-03-26 |
| CA3075872A1 (en) | 2019-03-21 |
| MX2020002889A (es) | 2020-10-01 |
| EP3681510A1 (en) | 2020-07-22 |
| JP2023038310A (ja) | 2023-03-16 |
| IL273126A (en) | 2020-04-30 |
| JP2020534270A (ja) | 2020-11-26 |
| MX2023010063A (es) | 2023-09-06 |
| US20220110949A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230201224A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| AU2015336463B2 (en) | Compositions and methods for treating insomnia | |
| US10722478B2 (en) | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine | |
| RU2718906C2 (ru) | Способы и композиции для лечения гипергидроза | |
| JP2018184440A (ja) | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 | |
| US20230165847A1 (en) | Methods of use of t-type calcium channel modulators | |
| JP2016074728A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| KR20190073385A (ko) | 결정성 양진의 치료법 | |
| HK40096830A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| US20220305012A1 (en) | Lemborexant for treating sleep issues | |
| RU2844395C2 (ru) | Лемборексант для лечения проблем со сном | |
| US20250375380A1 (en) | High strength single unit dose formulations and methods of use thereof | |
| US20250295646A1 (en) | Methods of use of t-type calcium channel modulators | |
| KR20250165616A (ko) | 고함량 단일 투여 단위 제형 및 이의 사용 방법 | |
| WO2024182654A1 (en) | High strength single unit dose formulations and methods of use thereof | |
| EP3989976A1 (en) | Lemborexant for treating sleep issues | |
| WO2024196957A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| WO2020263331A1 (en) | Lemborexant for treating sleep issues | |
| WO2024102802A1 (en) | Zelatriazin for the treatment of depression | |
| CN116916909A (zh) | 用于治疗睡眠呼吸暂停的瑞波西汀和毒蕈碱受体拮抗剂(mra)的组合 | |
| JP2023523569A (ja) | 神経学的および精神障害の治療方法 | |
| HK1145282B (en) | Treatment of sleep disorders |